Business
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
Strategic Appointment Enhances GeoVax’s Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc.
About this update from Geovax Labs, Inc.
[{"type":"text","content":"Strategic Appointment Enhances GeoVax’s Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Investigator at the Pandemic Sciences Institute (PSI). She served as one of the Principal Investigators who oversaw the Oxford/AstraZeneca vaccine program; she co-designed the vaccine in January 2020, led the preclinical studies, and oversaw the delivery of the immune results needed to support regulatory approval in late 2020. Professor Lambe was appointed as an honorary Officer of the Order of the British Empire (OBE) for her services to Sciences and Public Health in the 2021 Queen’s Birthday Honours and received the Presidential Distinguished Service Award for the Irish Abroad in 2022. In May 2024 she was elected a Fellow of the Academy of Medical Sciences, one of the most prestigious awards in the field. Professor Lambe’s research focuses on delineating the protective immune response post infection and using these findings to rationally design vaccination strategies to prevent disease. Her group is currently developing and testing vaccines against a number of outbreak pathogens including Crimean-Congo hemorrhagic fever, Ebola virus, Marburg virus and Coronaviruses. A number of these vaccines have progressed to clinical trial assessment, including vaccines against Ebola and Marburg virus. Dr. Mark Newman, GeoVax’s Chief Scientific Officer, commented, “We are thrilled to welcome Professor Lambe to our Scientific Advisory Board. Her extensive experience and groundbreaking work in vaccine development, particularly her pivotal role in the development of the Oxford/AstraZeneca COVID-19 vaccine, will be invaluable as we continue to advance our own vaccine and immunotherapy programs. Her expertise dovetails perfectly with our product portfolio, including the recent BARDA Project NextGen Award for the development of next-generation COVID-19 vaccines. Her insights will be crucial in accelerating our efforts to bring innovative solutions...